|
CA2799403C
(en)
|
2010-05-14 |
2020-01-21 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating leukemia
|
|
EP2571875A4
(en)
|
2010-05-14 |
2013-10-30 |
Dana Farber Cancer Inst Inc |
CONTRACEPTIVE COMPOSITIONS FOR MEN AND METHODS OF USE THEREOF
|
|
PL2571503T3
(pl)
|
2010-05-14 |
2015-06-30 |
Dana Farber Cancer Inst Inc |
Kompozycje i sposoby leczenia nowotworu, choroby zapalnej i innych zaburzeń
|
|
US20130225524A1
(en)
*
|
2010-11-05 |
2013-08-29 |
Deping Chai |
Chemical Compounds
|
|
US9249161B2
(en)
|
2010-12-02 |
2016-02-02 |
Constellation Pharmaceuticals, Inc. |
Bromodomain inhibitors and uses thereof
|
|
AR084070A1
(es)
|
2010-12-02 |
2013-04-17 |
Constellation Pharmaceuticals Inc |
Inhibidores del bromodominio y usos de los mismos
|
|
TW201307340A
(zh)
*
|
2010-12-06 |
2013-02-16 |
Piramal Life Sciences Ltd |
取代咪唑并喹啉衍生物
|
|
EP2705039B1
(en)
|
2011-05-04 |
2017-07-26 |
Constellation Pharmaceuticals, Inc. |
Bromodomain inhibitors and uses thereof
|
|
EP2721031B1
(en)
|
2011-06-17 |
2016-01-20 |
Constellation Pharmaceuticals, Inc. |
Bromodomain inhibitors and uses thereof
|
|
GB201114103D0
(en)
|
2011-08-17 |
2011-09-28 |
Glaxosmithkline Llc |
Novel compounds
|
|
WO2013027168A1
(en)
|
2011-08-22 |
2013-02-28 |
Pfizer Inc. |
Novel heterocyclic compounds as bromodomain inhibitors
|
|
WO2013033269A1
(en)
*
|
2011-08-29 |
2013-03-07 |
Coferon, Inc. |
Bioorthogonal monomers capable of dimerizing and targeting bromodomains and methods of using same
|
|
FI3461825T3
(fi)
*
|
2011-09-30 |
2023-08-17 |
C&C Res Lab |
Uusia heterosyklisiä johdannaisia ja niiden käyttöjä
|
|
WO2013097052A1
(en)
|
2011-12-30 |
2013-07-04 |
Abbott Laboratories |
Bromodomain inhibitors
|
|
EP2838881B1
(en)
|
2012-04-20 |
2018-08-08 |
AbbVie Inc. |
Isoindolone derivatives
|
|
EP2864336B1
(en)
|
2012-06-06 |
2016-11-23 |
Constellation Pharmaceuticals, Inc. |
Benzo[b]isoxazoloazepine bromodomain inhibitors and uses thereof
|
|
TWI602820B
(zh)
|
2012-06-06 |
2017-10-21 |
星宿藥物公司 |
溴域抑制劑及其用途
|
|
WO2013185284A1
(en)
|
2012-06-12 |
2013-12-19 |
Abbott Laboratories |
Pyridinone and pyridazinone derivatives
|
|
WO2013192274A2
(en)
|
2012-06-19 |
2013-12-27 |
The Broad Institute, Inc. |
Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy
|
|
US9422290B2
(en)
|
2012-11-13 |
2016-08-23 |
Boehringer Ingelheim International Gmbh |
Triazolopyridazine
|
|
US9266891B2
(en)
|
2012-11-16 |
2016-02-23 |
Boehringer Ingelheim International Gmbh |
Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors
|
|
US9073878B2
(en)
|
2012-11-21 |
2015-07-07 |
Zenith Epigenetics Corp. |
Cyclic amines as bromodomain inhibitors
|
|
WO2014080291A2
(en)
|
2012-11-21 |
2014-05-30 |
Rvx Therapeutics Inc. |
Biaryl derivatives as bromodomain inhibitors
|
|
US9271978B2
(en)
|
2012-12-21 |
2016-03-01 |
Zenith Epigenetics Corp. |
Heterocyclic compounds as bromodomain inhibitors
|
|
WO2014128655A1
(en)
*
|
2013-02-25 |
2014-08-28 |
Aurigene Discovery Technologies Limited |
Substituted imidazo[4,5-c]quinoline derivatives as bromodomain inhibitors
|
|
JP6401773B2
(ja)
|
2013-03-11 |
2018-10-10 |
ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン |
Ｂｅｔブロモドメイン阻害剤およびこれを用いる治療方法
|
|
US9670221B2
(en)
|
2013-03-14 |
2017-06-06 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Furopyridines as bromodomain inhibitors
|
|
WO2014159837A1
(en)
|
2013-03-14 |
2014-10-02 |
Convergene Llc |
Methods and compositions for inhibition of bromodomain-containing proteins
|
|
US9714946B2
(en)
|
2013-03-14 |
2017-07-25 |
Dana-Farber Cancer Institute, Inc. |
Bromodomain binding reagents and uses thereof
|
|
AU2014236606A1
(en)
*
|
2013-03-15 |
2015-09-24 |
Epigenetix, Inc. |
Oxazolo(5,4-c)quinolin-2-one compounds as bromodomain inhibitors
|
|
CA2903881C
(en)
|
2013-03-15 |
2021-05-18 |
Incyte Corporation |
Tricyclic heterocycles as bet protein inhibitors
|
|
JP6453845B2
(ja)
*
|
2013-03-27 |
2019-01-16 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｂｒｄ４阻害薬としてのジヒドロキナゾリノン類似体
|
|
US9102684B2
(en)
|
2013-03-27 |
2015-08-11 |
Boehringer Ingelheim International Gmbh |
Indolinone analogues
|
|
TWI530499B
(zh)
|
2013-03-28 |
2016-04-21 |
吉李德科學股份有限公司 |
作為溴結構域（ｂｒｏｍｏｄｏｍａｉｎ）抑制劑之苯並咪唑酮衍生物類
|
|
EA027139B1
(ru)
|
2013-04-26 |
2017-06-30 |
Бейджин, Лтд. |
Замещенные 5-(3,5-диметилизоксазол-4-ил)индолин-2-оны
|
|
PL2991683T3
(pl)
|
2013-05-02 |
2020-03-31 |
Glykos Finland Oy |
Koniugaty glikoproteiny lub glikanu z toksycznym ładunkiem
|
|
TWI527811B
(zh)
|
2013-05-09 |
2016-04-01 |
吉李德科學股份有限公司 |
作爲溴結構域抑制劑的苯並咪唑衍生物
|
|
US8975417B2
(en)
*
|
2013-05-27 |
2015-03-10 |
Novartis Ag |
Pyrazolopyrrolidine derivatives and their use in the treatment of disease
|
|
ES2656471T3
(es)
*
|
2013-05-28 |
2018-02-27 |
Novartis Ag |
Derivados de pirazolo-pirrolidin-4-ona como inhibidores de BET y su uso en el tratamiento de enfermedades
|
|
SG11201510409QA
(en)
|
2013-06-21 |
2016-01-28 |
Zenith Epigenetics Corp |
Novel bicyclic bromodomain inhibitors
|
|
CA2915622C
(en)
|
2013-06-21 |
2020-08-18 |
Zenith Epigenetics Corp. |
Novel substituted bicyclic compounds as bromodomain inhibitors
|
|
US9290514B2
(en)
|
2013-07-08 |
2016-03-22 |
Incyte Holdings Corporation |
Tricyclic heterocycles as BET protein inhibitors
|
|
WO2015013635A2
(en)
|
2013-07-25 |
2015-01-29 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of transcription factors and uses thereof
|
|
US9855271B2
(en)
|
2013-07-31 |
2018-01-02 |
Zenith Epigenetics Ltd. |
Quinazolinones as bromodomain inhibitors
|
|
WO2015049629A1
(en)
*
|
2013-10-01 |
2015-04-09 |
Piramal Enterprises Limited |
Imidazoquinoline compounds as bromodomain inhibitors
|
|
US9428513B2
(en)
|
2013-11-07 |
2016-08-30 |
Boehringer Ingelheim International Gmbh |
Triazolopyrazine
|
|
WO2015070020A2
(en)
|
2013-11-08 |
2015-05-14 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
|
|
US9108953B2
(en)
|
2013-11-26 |
2015-08-18 |
Gilead Sciences, Inc. |
Quinoline derivatives as bromodomain inhibitors
|
|
WO2015081203A1
(en)
|
2013-11-26 |
2015-06-04 |
Incyte Corporation |
Bicyclic heterocycles as bet protein inhibitors
|
|
WO2015081189A1
(en)
|
2013-11-26 |
2015-06-04 |
Incyte Corporation |
Bicyclic heterocycles as bet protein inhibitors
|
|
AU2013406206B2
(en)
*
|
2013-11-26 |
2017-07-20 |
Gilead Sciences, Inc. |
Quinoline derivatives as bromodomain inhibitors
|
|
WO2015092118A1
(en)
|
2013-12-17 |
2015-06-25 |
Orion Corporation |
Spiro[cyclobutane-1,3'-indolin]-2'-one derivatives as bromodomain inhibitors
|
|
WO2015095492A1
(en)
|
2013-12-19 |
2015-06-25 |
Incyte Corporation |
Tricyclic heterocycles as bet protein inhibitors
|
|
LT3092227T
(lt)
|
2014-01-09 |
2018-08-10 |
Orion Corporation |
Bicikliniai heterocikliniai dariniai kaip bromodomeno inhibitoriai
|
|
WO2015117087A1
(en)
|
2014-01-31 |
2015-08-06 |
Dana-Farber Cancer Institute, Inc. |
Uses of diazepane derivatives
|
|
KR20160115953A
(ko)
|
2014-01-31 |
2016-10-06 |
다나-파버 캔서 인스티튜트 인크. |
디아미노피리미딘 벤젠술폰 유도체 및 그의 용도
|
|
MX2016009976A
(es)
|
2014-01-31 |
2016-11-15 |
Dana Farber Cancer Inst Inc |
Derivados de diazepam y sus usos.
|
|
CA2940554A1
(en)
|
2014-02-28 |
2015-09-03 |
The Regents Of The University Of Michigan |
9h-pyrimido[4,5-b]indoles and related analogs as bet bromodomain inhibitors
|
|
CN106456653A
(zh)
|
2014-02-28 |
2017-02-22 |
腾沙治疗公司 |
高胰岛素血症相关病症的治疗
|
|
DK3674302T3
(da)
|
2014-04-23 |
2023-04-03 |
Incyte Holdings Corp |
1h-pyrrolo[2,3-c]pyridin-7(6h)-oner og pyrazolo[3,4-c]pyridin-7(6h)-oner som inhibitorer af bet-proteiner
|
|
NO2714752T3
(enExample)
*
|
2014-05-08 |
2018-04-21 |
|
|
|
US9428515B2
(en)
*
|
2014-05-09 |
2016-08-30 |
Boehringer Ingelheim International Gmbh |
Benzimidazole derivatives
|
|
ES2725928T3
(es)
|
2014-06-20 |
2019-09-30 |
Constellation Pharmaceuticals Inc |
Formas cristalinas de 2-((4S)-6-(4-clorofenil)-1-metil-4H-benzo[c]isoxazolo[4,5-e]azepin-4-il)acetamida
|
|
EP3160513B1
(en)
|
2014-06-30 |
2020-02-12 |
Glykos Finland Oy |
Saccharide derivative of a toxic payload and antibody conjugates thereof
|
|
CA2955077A1
(en)
|
2014-08-08 |
2016-02-11 |
Dana-Farber Cancer Institute, Inc. |
Dihydropteridinone derivatives and uses thereof
|
|
WO2016022902A1
(en)
|
2014-08-08 |
2016-02-11 |
Dana-Farber Cancer Institute, Inc. |
Diazepane derivatives and uses thereof
|
|
EP3194406B8
(en)
|
2014-09-15 |
2021-03-31 |
Incyte Corporation |
Tricyclic heterocycles for use as bet protein inhibitors
|
|
MX376748B
(es)
|
2014-10-27 |
2025-03-07 |
Tensha Therapeutics Inc |
Inhibidores del bromodominio.
|
|
EP3227281A4
(en)
|
2014-12-01 |
2018-05-30 |
Zenith Epigenetics Ltd. |
Substituted pyridinones as bromodomain inhibitors
|
|
US10179125B2
(en)
|
2014-12-01 |
2019-01-15 |
Zenith Epigenetics Ltd. |
Substituted pyridines as bromodomain inhibitors
|
|
HK1245248B
(en)
|
2014-12-11 |
2020-05-15 |
恒翼生物医药(上海)股份有限公司 |
Substituted heterocycles as bromodomain inhibitors
|
|
HK1245247A1
(zh)
|
2014-12-17 |
2018-08-24 |
恒翼生物医药科技(上海)有限公司 |
溴结构域的抑制剂
|
|
US10259809B2
(en)
|
2015-02-03 |
2019-04-16 |
Trillium Therapeutics Inc. |
Fluorinated imidazo[4,5-C]quinoline derivatives as inhibitors of bromodomain containing proteins
|
|
EP3262045A1
(en)
|
2015-02-27 |
2018-01-03 |
The Regents of The University of Michigan |
9h-pyrimido [4,5-b]indoles as bet bromodomain inhibitors
|
|
GB201504694D0
(en)
|
2015-03-19 |
2015-05-06 |
Glaxosmithkline Ip Dev Ltd |
Covalent conjugates
|
|
GB201504689D0
(en)
|
2015-03-19 |
2015-05-06 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
|
US10457677B2
(en)
*
|
2015-04-02 |
2019-10-29 |
Merck Patent Gmbh |
Imidazolonylquinolines and the use thereof as ATM kinase inhibitors
|
|
WO2016186453A1
(en)
*
|
2015-05-20 |
2016-11-24 |
Kainos Medicine, Inc. |
Quinoline derivatives as bromodomain inhibitors
|
|
WO2016196065A1
(en)
|
2015-05-29 |
2016-12-08 |
Genentech, Inc. |
Methods and compositions for assessing responsiveness of cancers to bet inhibitors
|
|
WO2016199943A1
(en)
*
|
2015-06-11 |
2016-12-15 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compounds
|
|
WO2016201370A1
(en)
|
2015-06-12 |
2016-12-15 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
|
JP2018527293A
(ja)
|
2015-06-16 |
2018-09-20 |
オリオン コーポレーション |
ブロモドメイン阻害剤としてのスピロ［シクロブタン−１，３’−インドリン］−２’−オン誘導体
|
|
WO2016203335A1
(en)
|
2015-06-18 |
2016-12-22 |
Pfizer Inc. |
Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
|
|
JP2018520124A
(ja)
|
2015-06-26 |
2018-07-26 |
テンシャ セラピューティクス，インコーポレイテッド |
Ｎｕｔ正中線癌の治療
|
|
CA2989265A1
(en)
|
2015-07-02 |
2017-01-05 |
Orion Corporation |
Bicyclic heterocycle derivatives as bromodomain inhibitors
|
|
KR20180035905A
(ko)
|
2015-08-10 |
2018-04-06 |
다나-파버 캔서 인스티튜트 인크. |
Bet 브로모도메인 억제제에 대한 저항성의 메카니즘
|
|
CA2994472A1
(en)
|
2015-08-11 |
2017-02-16 |
Neomed Institute |
Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticals
|
|
US10836742B2
(en)
|
2015-08-11 |
2020-11-17 |
Neomed Institute |
N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
|
|
ES2904258T3
(es)
|
2015-08-12 |
2022-04-04 |
Neomed Inst |
Bencimidazoles sustituidos, su preparación y su uso como productos farmacéuticos
|
|
KR20180049058A
(ko)
|
2015-09-11 |
2018-05-10 |
다나-파버 캔서 인스티튜트 인크. |
시아노 티에노트리아졸로디아제핀 및 그의 용도
|
|
JP2018526424A
(ja)
|
2015-09-11 |
2018-09-13 |
ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド |
アセトアミドチエノトリアゾロジアゼピンおよびこれらの使用
|
|
GB201516504D0
(en)
|
2015-09-17 |
2015-11-04 |
Astrazeneca Ab |
Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
|
|
RU2018112312A
(ru)
|
2015-09-22 |
2019-10-23 |
ГлаксоСмитКлайн Интеллекчуал Проперти (N2) Лимитед |
Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена
|
|
WO2017066876A1
(en)
|
2015-10-21 |
2017-04-27 |
Neomed Institute |
Substituted imidazopyridines, their preparation and their use as pharmaceuticals
|
|
AR106520A1
(es)
|
2015-10-29 |
2018-01-24 |
Incyte Corp |
Forma sólida amorfa de un inhibidor de proteína bet
|
|
CN114957291A
(zh)
|
2015-11-25 |
2022-08-30 |
达纳-法伯癌症研究所股份有限公司 |
二价溴结构域抑制剂及其用途
|
|
AU2016361441B2
(en)
*
|
2015-11-25 |
2021-08-12 |
Convergene Llc |
Bicyclic BET bromodomain inhibitors and uses thereof
|
|
US10519151B2
(en)
|
2016-01-28 |
2019-12-31 |
Neomed Institute |
Substituted [1,2,4]triazolo[4,3-A]pyridines, their preparation and their use as pharmaceuticals
|
|
AU2017219627B2
(en)
|
2016-02-15 |
2021-08-05 |
The Regents Of The University Of Michigan |
Fused 1,4-oxazepines and related analogs as BET bromodomain inhibitors
|
|
AU2017246452C1
(en)
|
2016-04-06 |
2021-06-03 |
The Regents Of The University Of Michigan |
MDM2 protein degraders
|
|
AU2017246453A1
(en)
|
2016-04-06 |
2018-11-08 |
The Regents Of The University Of Michigan |
Monofunctional intermediates for ligand-dependent target protein degradation
|
|
UY37191A
(es)
|
2016-04-07 |
2017-11-30 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Derivados de dibenzofurano para uso como inhibidores de bromodominio
|
|
US10934272B2
(en)
|
2016-04-07 |
2021-03-02 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Pyridyl derivatives as bromodomain inhibitors
|
|
SG11201808729WA
(en)
|
2016-04-12 |
2018-11-29 |
Univ Michigan Regents |
Bet protein degraders
|
|
BR112018071216A2
(pt)
|
2016-04-15 |
2019-02-05 |
Abbvie Inc |
inibidores de bromodomínios
|
|
CA3023765A1
(en)
|
2016-05-24 |
2017-11-30 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Pyridine dicarboxamide derivatives as bromodomain inhibitors
|
|
CA3220957A1
(en)
|
2016-06-20 |
2017-12-28 |
Incyte Corporation |
Crystalline solid forms of a bet inhibitor
|
|
EP3490552B1
(en)
|
2016-07-26 |
2022-11-23 |
University of Southern California |
Selective bromodomain inhibition of fungal bdf1
|
|
WO2018026877A1
(en)
|
2016-08-05 |
2018-02-08 |
Calitor Sciences, Llc |
Process for preparing substituted quinolin-4-ol compounds
|
|
GB201614934D0
(en)
|
2016-09-02 |
2016-10-19 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Chemical compounds
|
|
GB201614940D0
(en)
|
2016-09-02 |
2016-10-19 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Chemical compounds
|
|
GB201614939D0
(en)
|
2016-09-02 |
2016-10-19 |
Glaxosmithkline Ip Dev Ltd |
Crystalline hydrate
|
|
CN110072866A
(zh)
|
2016-09-13 |
2019-07-30 |
密执安大学评议会 |
作为bet蛋白降解剂的稠合的1,4-二氮杂*
|
|
US11466028B2
(en)
|
2016-09-13 |
2022-10-11 |
The Regents Of The University Of Michigan |
Fused 1,4-oxazepines as BET protein degraders
|
|
WO2018109271A1
(en)
|
2016-12-13 |
2018-06-21 |
Orion Corporation |
New bromodomain inhibitors
|
|
EP3577120A1
(en)
|
2017-02-03 |
2019-12-11 |
The Regents of The University of Michigan |
Fused 1,4-diazepines as bet bromodomain inhibitors
|
|
GB201703282D0
(en)
|
2017-03-01 |
2017-04-12 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Compounds
|
|
CN109384784B
(zh)
*
|
2017-08-10 |
2021-01-12 |
浙江海正药业股份有限公司 |
磺酰胺类衍生物、其制备方法及其在医药上的用途
|
|
WO2019055444A1
(en)
|
2017-09-13 |
2019-03-21 |
The Regents Of The University Of Michigan |
DEGRADATION AGENTS OF BROMODOMAIN BET PROTEIN WITH CLEAR BINDERS
|
|
GB201716369D0
(en)
|
2017-10-06 |
2017-11-22 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Compounds
|
|
GB201716392D0
(en)
|
2017-10-06 |
2017-11-22 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Compounds
|
|
GB201814167D0
(en)
|
2018-08-31 |
2018-10-17 |
Glaxosmithkline Ip No 2 Ltd |
Compounds
|
|
WO2020219168A1
(en)
|
2019-04-24 |
2020-10-29 |
Convergene, Llc |
Small molecule bromodomain inhibitors and uses thereof
|
|
US20230014730A1
(en)
|
2019-09-23 |
2023-01-19 |
Nanjing Zhengxiang Pharmaceuticals Co., Ltd. |
Phosphodiesterase inhibitors and use
|
|
WO2021061803A1
(en)
|
2019-09-23 |
2021-04-01 |
Nanjing Zhengxiang Pharmaceuticals Co., Ltd. |
Phosphodiesterase inhibitors and use
|
|
IL294526B1
(en)
*
|
2020-01-10 |
2025-10-01 |
Incyte Corp |
Tricyclic compounds as KRAS inhibitors
|
|
WO2021150613A1
(en)
|
2020-01-20 |
2021-07-29 |
Incyte Corporation |
Spiro compounds as inhibitors of kras
|
|
WO2021175432A1
(en)
|
2020-03-04 |
2021-09-10 |
Boehringer Ingelheim International Gmbh |
Method for administration of an anti cancer agent
|
|
CR20220584A
(es)
*
|
2020-04-16 |
2023-02-15 |
Incyte Corp |
Inhibidores de kras tricíclicos fusionados
|
|
WO2021231526A1
(en)
|
2020-05-13 |
2021-11-18 |
Incyte Corporation |
Fused pyrimidine compounds as kras inhibitors
|
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
|
US11999752B2
(en)
|
2020-08-28 |
2024-06-04 |
Incyte Corporation |
Vinyl imidazole compounds as inhibitors of KRAS
|
|
WO2022072783A1
(en)
|
2020-10-02 |
2022-04-07 |
Incyte Corporation |
Bicyclic dione compounds as inhibitors of kras
|
|
JP2023547892A
(ja)
*
|
2020-10-27 |
2023-11-14 |
アリーナ ファーマシューティカルズ， インコーポレイテッド |
５－ｈｔ２ａセロトニン受容体に関連する障害を処置するために有用な５－ｈｔ２ａセロトニン受容体のモジュレーターとしてのピリミジン誘導体
|
|
US20240376090A1
(en)
*
|
2020-10-27 |
2024-11-14 |
Arena Pharmaceuticals, Inc. |
Isoxazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disordered related thereto
|
|
US12077539B2
(en)
|
2021-03-22 |
2024-09-03 |
Incyte Corporation |
Imidazole and triazole KRAS inhibitors
|
|
CN115124524A
(zh)
*
|
2021-03-26 |
2022-09-30 |
浙江海正药业股份有限公司 |
三环类衍生物及其制备方法和用途
|
|
AU2022306671A1
(en)
|
2021-07-07 |
2024-01-25 |
Incyte Corporation |
Tricyclic compounds as inhibitors of kras
|
|
CA3229855A1
(en)
*
|
2021-08-31 |
2023-03-09 |
Incyte Corporation |
Naphthyridine compounds as inhibitors of kras
|
|
US20240316061A1
(en)
|
2021-09-17 |
2024-09-26 |
Institut Curie |
Bet inhibitors for treating pab1 deficient cancer
|
|
WO2023049697A1
(en)
|
2021-09-21 |
2023-03-30 |
Incyte Corporation |
Hetero-tricyclic compounds as inhibitors of kras
|
|
WO2023056421A1
(en)
|
2021-10-01 |
2023-04-06 |
Incyte Corporation |
Pyrazoloquinoline kras inhibitors
|
|
CR20240197A
(es)
|
2021-10-14 |
2024-08-07 |
Incyte Corp |
Compuestos de quinolina como inhibidores de kras
|
|
EP4511119A1
(en)
|
2022-04-19 |
2025-02-26 |
Nuevolution A/S |
Compounds active towards bromodomains
|